123 results about "Body fluid sample" patented technology

This invention relates to the field of intelligent information processing technology and discloses an intelligent assessment system for endometrial receptivity based on biosensor data processing. The system acquires signals of multiple types of biomarkers in bodily fluid samples through multi-channel biosensor detection and performs structured preprocessing and quantitative transformation. Based on this, it establishes object-level associations between biosensor data and multi-source information to construct a unified feature data system. Furthermore, it constructs a weighted heterogeneous assessment graph and introduces a manifold stochastic feature modeling mechanism to generate manifold feature data. The manifold features and original features are jointly input into a shared-parameter cyclic Transformer model. Through cyclic inference and consistency constraints, multi-round feature fusion is achieved, outputting the endometrial receptivity assessment result. This invention improves the multi-source data modeling capability and the stability and consistency of the assessment process.

The invention belongs to the technical field of medical body fluid sample collection, and provides an integrated saliva collection filter which comprises a collection tube, a sponge rod used for collecting saliva is detachably connected in the collection tube through an extrusion part, a filter assembly is arranged at one end of the collection tube, and the liquid inlet end of the filter assembly corresponds to the sponge rod; the flexible liquid storage mechanism comprises a liquid mixing assembly, the liquid mixing assembly is connected with the collecting pipe through a connecting base, a spring microbead one-way valve assembly and a buffer liquid storage assembly are arranged in the connecting base, and the liquid outlet end of the spring microbead one-way valve assembly is communicated with the liquid mixing assembly; the liquid outlet end of the filtering assembly is communicated with the liquid mixing assembly through a spring microbead one-way valve assembly, and an automatic liquid leakage assembly is arranged between the buffer liquid storage assembly and the filtering assembly. Saliva collection, filtration and buffer solution mixing can be completed in one step, and the device is small in size, convenient to store and transport, capable of being integrally discarded after being used, environmentally friendly and efficient.

A rapid diagnostic device for detecting multiple biomarkers in bodily fluid samples, particularly useful for disease screening including breast cancer. The device comprises a housing containing at least one test strip with a sample receiving zone, conjugate pad, and multiple test zones. The test strip utilizes specific materials including Cytiva GF / DVA and Ahlstrom 1667 sample pads, an Ahlstrom 6613 conjugate pad with carboxylated 150 nm gold nanoshell conjugates, and a Sartorius CN140 membrane with precisely positioned test and control zones. The device simultaneously detects multiple biomarkers, such as hCG and CA-15-3, using specific antibodies. Features include a built-in safety lancet, integrated buffer system, and compatibility with various sample types. Results are available within ten minutes, with options for quantitative analysis via a dedicated reader or smartphone application. This multi-biomarker approach potentially improves screening accuracy compared to single-marker tests, offering versatility for detecting various medical conditions.

A computer-implemented method for determining a numerical analyte result value corresponding to the concentration of an analyte in a sample of a subject's body fluid applied to a reagent test area includes: (a) determining the numerical analyte result value based on an image of the reagent test area by using an algorithm that takes into account one or more parameters, each parameter adapted to take two or more values; (b) displaying the numerical analyte result value, and / or the corresponding analyte value range, and / or a corresponding message on a display device; and (c) automatically checking for available updated values ​​for one or more parameters on a remote server before performing step (a), and updating the corresponding parameter value taken into account in step (a) for each available updated value.

A composition and method for preserving a wide variety of analyte classes, including but not limited to small molecules, peptides, proteins, nucleic acids, carbohydrates, and lipids, ensuring stability and reproducibility of their compartmental concentration over the time course of storage at room temperature, thus enabling cost-efficient tests and logistics for the analysis of these samples.

This invention relates to the field of medical data and discloses a method for real-time monitoring of the efficacy of traditional Chinese medicine, Mongolian medicine, and Western medicine based on biosensor technology. This method enables real-time monitoring of drug efficacy and personalized medication guidance. The process includes collecting real-time multimodal biosignals from the user's body surface or minimally invasive body fluid samples to obtain raw sensor signals and acquire sensor array output; extracting real-time pharmacokinetic characteristic signals based on a preset pharmacokinetic model and mapping them to efficacy assessment parameters according to drug type; comparing the efficacy assessment parameters with a preset safe and effective concentration range to generate real-time medication status indicators and dosage adjustment prompts. This invention designs quantitative assessment methods for different types of drugs, enabling real-time comparison to generate efficacy status codes and dosage adjustment suggestions. It comprehensively generates a medication guidance report and transmits it in real-time to the user or clinical monitoring end, allowing for immediate adjustment of the medication regimen and ensuring safe and effective medication.

The application finds that SDF4 in a body fluid sample can become a marker for detecting cancer patients with good sensitivity and specificity. By using a reagent for specifically detecting SDF4, gastric cancer, breast cancer, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, liposarcoma, bladder cancer, brain tumor, head and neck cancer, gallbladder cancer, ovarian cancer, tongue cancer, or uterine cancer can be detected. The measurement of SDF4 in a body fluid sample is a detection method capable of detecting various cancers by a single test, and can be used for large-scale screening of cancers. In addition, early-stage cancers can be detected with good sensitivity and specificity, so that cancers can be found and treated in an early stage.

The invention relates to the technical field of biomedical detection, in particular to a multi-dimensional tumor marker joint detection device and a using method thereof.The device comprises a sample processing module, a sequencing module, a marker extraction module, a feature fusion and detection module and a result output module, and 6 types of markers such as chromosome copy variation, microsatellite instability and the like are extracted respectively. The method comprises the following steps: collecting a body fluid sample to extract cfDNA, directly constructing a library without special treatment, obtaining effective data through whole genome sequencing, synchronously extracting six types of markers through each module of the device, optimizing an algorithm to adapt to low-depth data, inputting an integrated learning model to output a risk score, and finally outputting related information by a result output module. The method does not need special experimental treatment, realizes low-cost and high-accuracy joint detection, and meets the clinical large-scale screening requirements.

A method of detecting an analyte in a body fluid sample using a mobile device having a camera. An image is obtained with the camera of a test field having the body fluid sample applied thereto, causing an optical detection reaction. An algorithm is then performed to determine a potential detection of an optical detection feature and a potential item of intensity information. The potential item of intensity information is weighted with a known item of position probability information. The known item of position probability information is a probability of a potential item of intensity information on the optical detection reaction being a valid item of intensity information. The analyte is detected considering the weighted potential item of intensity information for differentiating a valid from an invalid item of intensity information. A calibration process is then performed in which the known item of position probability information is selected.

The invention is applicable to the field of in-vitro diagnostic equipment, and discloses a sample analyzer. The sample analyzer comprises a sample introduction device, a sample distribution device, a first visible component detection device, a second visible component detection device and a controller, wherein the first visible component detection device comprises a first microscopic imaging device. The controller is configured to at least output a kinetic analysis result of sperms in the semen sample according to an image obtained by executing a first shooting action on the semen sample by the first microscopic imaging device; and at least outputting a morphological analysis result of at least part of the visible components in the first body fluid sample according to detection data obtained by performing the visible component detection action on the first body fluid sample by the second visible component detection device. According to the invention, one sample analyzer can be used for carrying out visible component analysis on a semen sample and another type of body fluid sample, so that the purchase, use and maintenance cost of the sample analyzer for analyzing the semen sample can be reduced.

The present invention describes a comprehensive system and method for the simultaneous early detection of multiple cancers in a single analysis. The system involves a liquid chromatography-mass spectrometry (LC-MS) instrument coupled with a processor and AI / ML algorithms. The LC-MS instrument analyzes metabolite ions from dried extracts of biological fluid samples and aligns and normalizes the data while minimizing errors. Quality control processes, including neural network models and critical ion monitoring, ensure accurate detection. The system employs an AI / ML process to create two models: a Cancer Detection AI (CDAI) model for identifying cancer samples and a Tissue of Origin Identification (TOOAI) model for distinguishing specific cancer types. These models are applied to test samples and provide a score based on tissue of origin probability. The present invention aims to revolutionize early cancer detection through advanced analytical and machine learning techniques.

A method for detecting cancer or predicting a cancer prognosis is provided. The method involves the detection of Tetraspanin 10 in a sample of bodily fluid from a subject.

This invention discloses a method and system for assessing tumor content in liquid biopsies. The method performs quality control on high-throughput sequencing data from body fluid samples, filtering germline variations, clonal hematopoietic-related variations, and sequencing errors to obtain copy number variation (CNV) information and somatic mutation characteristic information. A weighted mean squared error loss function is constructed based on the CNV information, and the tumor content is solved using a constrained gradient descent method. When the CNV signal does not meet preset judgment conditions, the system switches to the mutation characteristic module, constructing a negative log-likelihood function based on a binomial distribution based on the principal clonal cluster, and solving for the tumor content through iterative optimization. In extreme cases, a backoff mechanism is triggered. This invention combines the stability of CNV at high tumor content with the sensitivity of mutational VAF at low content, achieving adaptive assessment from low to high tumor content.

The invention relates to new chemical compounds and combinations of chemical compounds, for medical use, more specifically for cancer diagnosis, in particular for the detection of activity specific for pancreatic cancer and in the diagnosis of pancreatic cancer. The invention relates also to an in vitro method for the detection of enzymatic activity present in an individual's body fluid sample, using such a compound or combination. The invention further relates to an in vitro method for the diagnosis of pancreatic cancer, using such a compound or combination, a kit comprising such a compound or combination, and the use of such a compound or combination for detecting enzymatic activity specific for pancreatic cancer and the use of such a compound or combination for the diagnosis of pancreatic cancer. The invention relates furthermore to such a compound or combination of compounds for use as a diagnostic marker for pancreatic cancer, and a method for the treatment of pancreatic cancer comprising the step of carrying out the method for the diagnosis of pancreatic cancer as defined above using such a compound or combination.

The invention provides methods for assessing immune system function and status based on cellular analysis. Methods of the present invention involve obtaining mass properties of immune cells collected in a tissue or body fluid sample from a subject. Such mass properties may include the mass of one or more immune cells and / or changes in mass of such immune cells over a period of time. Such data is then used for determining a status of the subject's immune response, and subsequent diagnosis and treatment of an infection or immunological disease or dysfunction.

1. The name of the design product: microorganism culture monitor. 2. The use of the design product: for culturing, detecting aerobic bacteria, anaerobic bacteria, fungi and mycobacteria in blood and body fluid samples. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view 1.

Subject matter of the present invention is an angiotensin-receptor-agonist and / or a precursor thereof for use in the treatment of a disease in a subject, • wherein said disease is selected from the group comprising heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, severe infection (microbial, viral (e.g. AIDS), parasitic diseases (e.g. Malaria)), SIRS or sepsis, cancer, acute kidney injury (AKI), CNS disorders (e.g. seizures, neurodegenerative diseases), autoimmune diseases, vascular diseases, hypotension and shock, and • wherein said subject has an amount of DPP3 protein and / or DPP3 activity in a sample of bodily fluid that is above a predetermined threshold.

The present application relates to a marker and a method for detecting inflammation-related diseases. The marker of the present application can stably exist in an ex vivo body fluid sample and does not gather on a cell membrane, so the detection result is very accurate. The marker can be widely applied to the medical detection of inflammation-related diseases, having good clinical application prospects.

The invention relates to a method of detecting cancer in a subject based on the level of p53 protein aggregates in a body fluid sample from the subject. The invention also relates to corresponding methods of determining the risk of cancer in a subject, monitoring the progression or onset of cancer, and / or determining the efficacy of a therapeutic intervention for treating cancer in a subject. The invention further relates to kits for use said methods.

The invention relates to the technical field of body fluid sampling detection, in particular to a neurology body fluid sampling detection device based on sterile operation, which comprises a detection table, a base table is fixedly mounted on one side of the top of the detection table, a machine frame is fixedly mounted in the center of the top of the base table, and a turntable is rotatably mounted in the machine frame; a plurality of mounting grooves are evenly formed in the top of the rotary disc in the circumferential direction, an outer sleeve frame is fixedly mounted in each mounting groove, and an inner sleeve frame is slidably mounted in an inner cavity of each outer sleeve frame. By combining the revolution and rotation compound motion of the turntable and multi-power adjustment, samples can be efficiently and uniformly mixed, the gradient uniform shaking layering requirement can be met, the sterile environment can be guaranteed through the arc-shaped baffle plate, meanwhile, the operation stability is improved by virtue of the positioning locking mechanism, and the efficiency and the safety of body fluid sampling detection in the neurology department are greatly improved.

The invention discloses a physiological index monitoring and drug delivery integrated system and an application thereof in wearable equipment, through integration of a microneedle array, a fluid chamber area, a piezoelectric sensing module, a drug controlled release module and a signal processing module, real-time monitoring of physiological indexes and automatic drug delivery are realized by using a double-chamber structure. The fluid chamber area is composed of a first fluid chamber and a second fluid chamber, the first fluid chamber and the second fluid chamber guide the flowing direction of a body fluid sample and medicine in a one-way mode through a microfluid channel and a one-way valve, and the first chamber is used for receiving and guiding the body fluid sample to the piezoelectric sensing module for physiological detection. The second chamber guides the medicine to the microneedle array for accurate delivery to realize real-time monitoring of physiological indexes and automatic medicine delivery, the piezoelectric sensing module guides a body fluid sample to the sensing unit and detects physiological parameters based on the acoustic surface wave effect, and the signal processing module controls the dosage of the medicine according to the detection result. And precise drug release is realized through the drug controlled release module.

The invention provides a portable body fluid sample sampling device which comprises a collecting assembly, a storage assembly and a connecting assembly, the collecting assembly is used for collecting a body fluid sample and separating an initial section sample from a middle section sample, and the storage assembly is used for storing the middle section sample; the connecting assembly is used for realizing detachable connection between the collecting assembly and the storage assembly and controlling conduction and disconnection of a body fluid sample; one end of the connecting assembly is fixedly connected with the collecting assembly, and the other end of the connecting assembly is detachably connected with the storage assembly; through combination of the collection assembly, the storage assembly and the connection assembly, collection of a body fluid sample and automatic separation of a primary sample and a middle sample can be realized, the problems of sample mixing and low purity caused by lack of a separation mechanism of an existing device are solved, the middle sample keeps relatively high purity, and the detection accuracy is improved. Therefore, the accuracy and the reliability of subsequent clinical examination are remarkably improved.

This invention relates to the field of medical supplies technology, specifically to an intelligent transfer cabinet for body fluid specimens. The cabinet comprises a cabinet body, a partitioned storage system, a control unit (i.e., an industrial-grade main controller), and a communication and control execution module. The cabinet body is integrally formed from 304 stainless steel and includes multiple physically isolated specimen storage areas and a low-temperature storage area. The main controller, based on an ARM Cortex-A series processor and equipped with an embedded system, serves as the core for managing all modules. The communication module enables data interaction with the hospital information system, and the control execution module, controlled by the main controller, centrally manages the electromagnetic locks and status indicators of each storage compartment door. This invention achieves standardized and intelligent temporary storage and transfer of body fluid specimens, improving management automation and reliability, and ensuring storage hygiene and safety as well as the integrity of information management.

A microfluidic device (12) for applying a sample of body fluid to a conditioned sensor element for the detection of molecular biomarkers in the body fluid and / or for conditioning the sensor element (14) using a conditioning fluid comprises at least one interaction chamber (40) that is partially closed by a sensor element (14). A pneumatic unit (70) is connected to the at least one first receptacle (46) and is configured to pressurize it and pump the body fluid or the conditioning fluid once and unidirectionally through the at least one interaction chamber (40) along the treated surface (16) and subsequently into the at least one disposal container (52), so that, in the case of body fluid, biomarkers adhere to the surface (16) or, in the case of conditioning fluid, the surface is conditioned.Furthermore, a biomarker detection device (18) and a method for applying a sample of body fluid to a conditioned sensor element (14) for biomarker detection and / or for conditioning a sensor element (14) for biomarker detection are proposed.

A method and a system for evaluating a drug concentration in body fluid samples, wherein the body fluid samples are blood, plasma or serum, the method including the steps of: preparing at least one body fluid sample including a solved target drug by removing unsolved components from the body fluid sample; performing absorption spectrophotometric analyzes on the at least one body fluid sample; and evaluating a drug concentration in the at least one body fluid sample based on the spectrophotometric analyzes.

The invention provides a reference electrode for a potentiometric measurement system for measuring an analyte in a body fluid sample, comprising an Ag / AgCl conductor element (8) in contact with a reference electrolyte (7) wherein the chloride ion (Cl-) concentration in the reference electrolyte (7) is between 50 mmol / L and 200 mmol / L, and wherein the sodium ion (Na +) concentration in the reference electrolyte (7) is preferably between 70 mmol / L and 270 mmol / L, and wherein the Ag / AgCl conductor element (8) is in contact with the reference electrolyte (7). And wherein the ionic strength of the reference electrolyte (7) is between 75 mmol / L and 300 mmol / L. The invention also provides a potentiometric measurement system and a method for potentiometric measurement of an analyte in a body fluid sample.

This invention relates to the field of biological sample processing technology, and provides a method and apparatus for extracting exosomes from body fluids. The apparatus includes: a liquid-filling tube, with a filter at the opening for filtering body fluid samples, and an exosome capturing agent inside the liquid-filling tube; a cap for sealing the opening of the liquid-filling tube; and a magnetic sleeve, with a magnet built into its sidewall or bottom for accommodating the liquid-filling tube and adsorbing the magnetic components in the exosome capturing agent. The exosome capturing agent is composed of a mixture of magnetic microspheres conjugated with various exosome-specific antibodies. This invention eliminates the need for expensive equipment such as ultracentrifuges, completes extraction within one hour, achieves a recovery rate of 85%, a lipoprotein removal rate of 92%, and effectively protects the integrity of exosomes. It is suitable for rapid detection and home self-testing of various body fluids such as blood and urine.

An analytical system and method for determining at least one characteristic of at least one sample of bodily fluid is disclosed. The method includes using at least one first mobile device (112) and at least one second mobile device (114), each of which includes at least one camera (116) and at least one processor (118). Prior to applying the sample of bodily fluid to a reagent testing area (122), at least one first image is acquired by the first mobile device (112). The first image is stored in a database (128) along with a time stamp and at least one first identifying information. The second mobile device (114) acquires at least one second image and determines at least one characteristic of the sample by using the information of the first mobile device (112) stored in the database (128).

Subject of the invention are DPP3 binders for use in therapy or prevention of endothelial dysfunction in a patient wherein the level of Pro-Adrenomedullin or a fragment thereof in a sample of bodily fluid obtained from said patient is above a threshold, as well as methods of therapy guidance or therapy stratification or therapy monitoring of a treatment of a patient with a DPP3 binder, the methods comprising: providing a sample of bodily fluid of said patient; determining the level of Pro-Adrenomedullin or a fragment thereof in said sample; and comparing said level of Pro-Adrenomedullin or a fragment thereof to a threshold; wherein the level of Pro-Adrenomedullin or a fragment thereof in said sample being above said threshold is indicative that said patient requires treatment with a DPP3 binder, or wherein if said level of Pro-Adrenomedullin or a fragment thereof in said sample is above said threshold, said patient is treated with a DPP3 binder.